These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 18539344)

  • 1. Mutations close to functional motif IV in HSV-1 UL5 helicase that confer resistance to HSV helicase-primase inhibitors, variously affect virus growth rate and pathogenicity.
    Biswas S; Tiley LS; Zimmermann H; Birkmann A; Field HJ
    Antiviral Res; 2008 Oct; 80(1):81-5. PubMed ID: 18539344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single amino acid substitutions in the HSV-1 helicase protein that confer resistance to the helicase-primase inhibitor BAY 57-1293 are associated with increased or decreased virus growth characteristics in tissue culture.
    Biswas S; Jennens L; Field HJ
    Arch Virol; 2007; 152(8):1489-500. PubMed ID: 17404685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A single drug-resistance mutation in HSV-1 UL52 primase points to a difference between two helicase-primase inhibitors in their mode of interaction with the antiviral target.
    Biswas S; Kleymann G; Swift M; Tiley LS; Lyall J; Aguirre-Hernández J; Field HJ
    J Antimicrob Chemother; 2008 May; 61(5):1044-7. PubMed ID: 18299638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of therapy using a helicase-primase inhibitor (HPI) in mice infected with deliberate mixtures of wild-type HSV-1 and an HPI-resistant UL5 mutant.
    Sukla S; Biswas S; Birkmann A; Lischka P; Ruebsamen-Schaeff H; Zimmermann H; Field HJ
    Antiviral Res; 2010 Jul; 87(1):67-73. PubMed ID: 20420855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of virus strains resistant to the herpes virus helicase-primase inhibitor ASP2151 (Amenamevir).
    Chono K; Katsumata K; Kontani T; Shiraki K; Suzuki H
    Biochem Pharmacol; 2012 Aug; 84(4):459-67. PubMed ID: 22687623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isolation and characterization of herpes simplex virus type 1 resistant to aminothiazolylphenyl-based inhibitors of the viral helicase-primase.
    Liuzzi M; Kibler P; Bousquet C; Harji F; Bolger G; Garneau M; Lapeyre N; McCollum RS; Faucher AM; Simoneau B; Cordingley MG
    Antiviral Res; 2004 Dec; 64(3):161-70. PubMed ID: 15550269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of HSV-1 variants highly resistant to the helicase-primase inhibitor BAY 57-1293 at high frequency in 2 of 10 recent clinical isolates of HSV-1.
    Biswas S; Smith C; Field HJ
    J Antimicrob Chemother; 2007 Aug; 60(2):274-9. PubMed ID: 17550887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ASP2151, a novel helicase-primase inhibitor, possesses antiviral activity against varicella-zoster virus and herpes simplex virus types 1 and 2.
    Chono K; Katsumata K; Kontani T; Kobayashi M; Sudo K; Yokota T; Konno K; Shimizu Y; Suzuki H
    J Antimicrob Chemother; 2010 Aug; 65(8):1733-41. PubMed ID: 20534624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A mutation in helicase motif IV of herpes simplex virus type 1 UL5 that results in reduced growth in vitro and lower virulence in a murine infection model is related to the predicted helicase structure.
    Biswas S; Miguel RN; Sukla S; Field HJ
    J Gen Virol; 2009 Aug; 90(Pt 8):1937-1942. PubMed ID: 19403757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease.
    Crute JJ; Grygon CA; Hargrave KD; Simoneau B; Faucher AM; Bolger G; Kibler P; Liuzzi M; Cordingley MG
    Nat Med; 2002 Apr; 8(4):386-91. PubMed ID: 11927945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High conservation of herpes simplex virus UL5/UL52 helicase-primase complex in the era of new antiviral therapies.
    Collot M; Rouard C; Brunet C; Agut H; Boutolleau D; Burrel S
    Antiviral Res; 2016 Apr; 128():1-6. PubMed ID: 26826441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of herpes simplex virus replication by a 2-amino thiazole via interactions with the helicase component of the UL5-UL8-UL52 complex.
    Spector FC; Liang L; Giordano H; Sivaraja M; Peterson MG
    J Virol; 1998 Sep; 72(9):6979-87. PubMed ID: 9696789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiviral drug resistance and helicase-primase inhibitors of herpes simplex virus.
    Field HJ; Biswas S
    Drug Resist Updat; 2011 Feb; 14(1):45-51. PubMed ID: 21183396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High frequency of spontaneous helicase-primase inhibitor (BAY 57-1293) drug-resistant variants in certain laboratory isolates of HSV-1.
    Biswas S; Swift M; Field HJ
    Antivir Chem Chemother; 2007; 18(1):13-23. PubMed ID: 17354648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Herpes simplex virus helicase-primase inhibitors: recent findings from the study of drug resistance mutations.
    Biswas S; Field HJ
    Antivir Chem Chemother; 2008; 19(1):1-6. PubMed ID: 18610552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease.
    Kleymann G; Fischer R; Betz UA; Hendrix M; Bender W; Schneider U; Handke G; Eckenberg P; Hewlett G; Pevzner V; Baumeister J; Weber O; Henninger K; Keldenich J; Jensen A; Kolb J; Bach U; Popp A; Mäben J; Frappa I; Haebich D; Lockhoff O; Rübsamen-Waigmann H
    Nat Med; 2002 Apr; 8(4):392-8. PubMed ID: 11927946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Helicase primase inhibitors (HPIs) are efficacious for therapy of human herpes simplex virus (HSV) disease in an infection mouse model.
    Uhlig N; Donner AK; Gege C; Lange F; Kleymann G; Grunwald T
    Antiviral Res; 2021 Nov; 195():105190. PubMed ID: 34666109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mismatch primer-based PCR reveals that helicase-primase inhibitor resistance mutations pre-exist in herpes simplex virus type 1 clinical isolates and are not induced during incubation with the inhibitor.
    Sukla S; Biswas S; Birkmann A; Lischka P; Zimmermann H; Field HJ
    J Antimicrob Chemother; 2010 Jul; 65(7):1347-52. PubMed ID: 20453068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. UL52 primase interactions in the herpes simplex virus 1 helicase-primase are affected by antiviral compounds and mutations causing drug resistance.
    Muylaert I; Zhao Z; Elias P
    J Biol Chem; 2014 Nov; 289(47):32583-92. PubMed ID: 25278021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA polymerase mutations in drug-resistant herpes simplex virus mutants determine in vivo neurovirulence and drug-enzyme interactions.
    Andrei G; Fiten P; Froeyen M; De Clercq E; Opdenakker G; Snoeck R
    Antivir Ther; 2007; 12(5):719-32. PubMed ID: 17713155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.